Novartis
Executive Summary
This appears to be incomplete or erroneous data, as Novartis is a major Swiss multinational pharmaceutical company headquartered in Basel, not a Chinese entity. Novartis AG is a global pharma leader with extensive R&D capabilities and active BD operations. If this refers to Novartis' Chinese operations, they maintain significant presence in China but carry no BIOSECURE risk as a Swiss-domiciled company. The lack of data suggests a data collection error requiring immediate clarification.
Structure: Unable to assess corporate structure due to data inconsistency - Novartis is a Swiss public company (SIX: NOVN, NYSE: NVS), not a Chinese entity. If referring to Novartis China operations, these would be wholly-owned foreign enterprises (WOFEs) under the Swiss parent. Requires data verification before proceeding with any structural analysis.
Ownership & Shareholder Structure
Zai Lab → Novartis
Zai Lab in-licensed multiple Novartis assets for Greater China including KRAS G12C inhibitor.
Pharmaron → Novartis
Pharmaron provides drug discovery and development services to Novartis.
Tigermed → Novartis
Tigermed provides clinical trial management services to Novartis in China.
BIOSECURE Risk
Novartis is a Swiss company with no BIOSECURE exposure; if this refers to partnerships with Chinese entities, assessment would depend on specific relationship structure
Mitigation: Not applicable for Swiss-domiciled Novartis AG
BD Intelligence
Therapeutic Areas:
Recent Deals: Unable to assess due to data inconsistency
Approach: Clarify entity identity before engagement - if this is Novartis AG, they are a potential partner/competitor, not acquisition target
Red Flags
- ⚠Major data inconsistency - Novartis is Swiss, not Chinese
- ⚠Incomplete entity information raises data quality concerns
- ⚠Potential confusion between Novartis AG and a different Chinese entity
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 6
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.